Back to results
US 10,206,885 B2Granted
Nanogel-mediated drug delivery
AssigneeThe Cleveland Clinic Foundation
InventorsVinod Labhasetwar, Sivakumar Vijayaraghavalu
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Cleveland Clinic Foundation
InventorsVinod Labhasetwar, Sivakumar Vijayaraghavalu
Estimating the term…
Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.
A method of inhibiting proliferation of one or more tumor cells in a human in need thereof comprising contacting the one or more tumor cells with a therapeutically effective amount of a nanogel composition comprising decitabine and doxorubicin, wherein the decitabine and doxorubicin are encapsulated in the same nanogel, wherein the doxorubicin is loaded in the nanogel's core and the decitabine is loaded in the nanogel's corona, and wherein the decitabine and doxorubicin are sequentially delivered to the tumor cells with decitabine released first and doxorubicin released later.
A method of treating a tumor, metastasis of a tumor or a combination thereof, said tumor comprising tumor cells, in a human in need thereof comprising administering a therapeutically effective amount of a nanogel composition comprising decitabine and doxorubicin, wherein the decitabine and doxorubicin are encapsulated in the same nanogel, wherein the doxorubicin is loaded in the nanogel's core and the decitabine is loaded in the nanogel's corona, and wherein the decitabine and doxorubicin are sequentially delivered to the tumor cells with decitabine released first and doxorubicin released later.
A method of sequentially delivering decitabine and doxorubicin to an individual that has a tumor, comprising administering a therapeutically effective amount of a nanogel composition comprising decitabine and doxorubicin to the individual, wherein the decitabine and doxorubicin are encapsulated in the same nanogel, wherein the doxorubicin is loaded in the nanogel's core and the decitabine is loaded in the nanogel's corona, and wherein the decitabine and doxorubicin are sequentially delivered to the tumor cells with decitabine released first and doxorubicin released later.
Dependencies are inferred from the claim text.